



ClinicalTrialTransparency
AstraZeneca R&D
S-151 85 Södertälje
Sweden

Date: 7 February 2014

Subject: NIS-OTW-DUM-2008/1 study status

To whom it may concern:

Study code NIS-OTW-DUM-2008/1: An Observational Study Comparing Efficacy Between Anti-microtubule Agents, and Non-anti-microtubule Agents as the Third-line Therapy in Patients with Non-Small Cell Lung Cancer of Adeno Histology Who Received the Second-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy, this is to confirm there were no data analysis and the CSR Synopsis is unavailable.

Yours sincerely,

A handwritten signature in cursive script, appearing to read "Aparna Chouhan".